Expression of TIP60 (tat‐interactive protein) and MRE11 (meiotic recombination 11 homolog) predict treatment‐specific outcome of localised invasive bladder cancer

What's known on the subject? and What does the study add?

[1]  A. Agaimy,et al.  Expression of p16INK4A in gastrointestinal stromal tumours (GISTs): two different forms exist that independently correlate with poor prognosis , 2010, Histopathology.

[2]  P 53 as a prognostic marker for bladder cancer : a meta-analysis and review , 2005 .

[3]  N. Malats,et al.  P53 as a prognostic marker for bladder cancer: a meta-analysis and review. , 2005, The Lancet. Oncology.

[4]  Alun D. Hughes,et al.  The interaction of the SRA domain of ICBP90 with a novel domain of DNMT1 is involved in the regulation of VEGF gene expression , 2008, Oncogene.

[5]  Ananya Choudhury,et al.  MRE11 expression is predictive of cause-specific survival following radical radiotherapy for muscle-invasive bladder cancer. , 2010, Cancer research.

[6]  A. Niemierko,et al.  Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience. , 2012, European urology.

[7]  G. Bussolati,et al.  Technical pitfalls potentially affecting diagnoses in immunohistochemistry , 2008, Journal of Clinical Pathology.

[8]  J. Alsner,et al.  Retinoblastoma protein expression is an independent predictor of both radiation response and survival in muscle-invasive bladder cancer , 2003, British Journal of Cancer.

[9]  J. Gerdes,et al.  New Ki-67-equivalent murine monoclonal antibodies (MIB 1-3) generated against bacterially expressed parts of the Ki-67 cDNA containing three 62 base pair repetitive elements encoding for the Ki-67 epitope. , 1993, Laboratory investigation; a journal of technical methods and pathology.

[10]  T. Ørntoft,et al.  High expression of karyopherin-α2 defines poor prognosis in non-muscle-invasive bladder cancer and in patients with invasive bladder cancer undergoing radical cystectomy. , 2011, European urology.

[11]  J. Bartek,et al.  ATM Activation in Normal Human Tissues and Testicular Cancer , 2005, Cell cycle.

[12]  A. Goel,et al.  Re: Jason A. Efstathiou, Daphna Y. Spiegel, William U. Shipley, et al. Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience. Eur Urol 2012;61:705-11. , 2012, European urology.

[13]  S. Shariat,et al.  p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  J. Witjes,et al.  Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines. , 2011, European urology.

[15]  C. Rödel,et al.  Trimodality treatment and selective organ preservation for bladder cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  M. Yaffe,et al.  The combined status of ATM and p53 link tumor development with therapeutic response. , 2009, Genes & development.

[17]  T. Ørntoft,et al.  SMARCC1 expression is upregulated in prostate cancer and positively correlated with tumour recurrence and dedifferentiation. , 2008, Histology and histopathology.

[18]  J. Bartek,et al.  An immunochemical analysis of the human nuclear phosphoprotein p53. New monoclonal antibodies and epitope mapping using recombinant p53. , 1992, Journal of immunological methods.

[19]  A. Bossi.  Re: Arnulf Stenzl, Nigel C. Cowan, Maria De Santis, et al. Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU Guidelines. Eur Urol 2011;59:1009-18. , 2011, European urology.

[20]  Xiaofeng Jiang,et al.  Tip60: Connecting chromatin to DNA damage signaling , 2010, Cell cycle.

[21]  F. Waldman,et al.  Evaluation of Ki 67 , p 53 and angiogenesis in patients enrolled in a randomized study of neoadjuvant chemotherapy with or without cystectomy : A Southwest Oncology Group study , 2006 .

[22]  A. Hart,et al.  Apoptosis, proliferation and p53, cyclin D1, and retinoblastoma gene expression in relation to radiation response in transitional cell carcinoma of the bladder. , 2001, International journal of radiation oncology, biology, physics.

[23]  F. Waldman,et al.  Evaluation of Ki67, p53 and angiogenesis in patients enrolled in a randomized study of neoadjuvant chemotherapy with or without cystectomy: a Southwest Oncology Group Study. , 2006, Oncology reports.

[24]  J. Dunst,et al.  Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  S. Hamilton-Dutoit,et al.  HPV-associated p16-expression and response to hypoxic modification of radiotherapy in head and neck cancer. , 2010, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[26]  A. Kibel,et al.  Radiotherapy with or Without Chemotherapy in Muscle-Invasive Bladder Cancer , 2012 .

[27]  J. Petrini,et al.  The MRE11 complex: starting from the ends , 2011, Nature Reviews Molecular Cell Biology.

[28]  S. Shariat,et al.  Immunohistochemical biomarkers for bladder cancer prognosis , 2011, International journal of urology : official journal of the Japanese Urological Association.

[29]  Y. Lotan,et al.  Ki-67 Is an Independent Predictor of Bladder Cancer Outcome in Patients Treated with Radical Cystectomy for Organ-Confined Disease , 2006, Clinical Cancer Research.

[30]  A. Kiltie,et al.  Similar treatment outcomes for radical cystectomy and radical radiotherapy in invasive bladder cancer treated at a United Kingdom specialist treatment center. , 2008, International journal of radiation oncology, biology, physics.

[31]  S. Groshen,et al.  Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  M. Benavides,et al.  Conservative treatment with transurethral resection, neoadjuvant chemotherapy followed by radiochemotherapy in stage T2-3 transitional bladder cancer , 2006, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.